Zepbound is similar to other GLP-1 weight-loss medications like semaglutide (Wegovy) and liraglutide (Saxenda)
The glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and now next-generation multi-agonists that include GLP-1 activity, are producing average weight reductions far larger than previously expected from drugs, reshaping clinical practice and how clinicians and patients think about obesity treatment
Petersburg Institute of Bioregulation and Gerontology, primarily overseen by Vladimir Khavinson, in Russia, [2] [4] [5] [6] [7] though in recent years research using epitalon has started to be conducted elsewhere, focusing mainly on its ability to extend telomere length
d-Allulose contributes no calories but substantial sweetness equivalent to glucose and 70% of sucrose 14,15 , yielding a zero-calorie sweetener
Hunaiti AA et al
Some patients benefit from dose pauses or temporary reductions, while others find anxiety subsides naturally within 6-8 weeks of consistent use